Tirzepatide Explained
The Next Generation of GLP-1 Based Weight Loss
Medically reviewed by Dr. Ana Lisa Carr, MD
Tirzepatide is a dual GIP/GLP-1 receptor agonist that represents the latest advancement in medical weight loss. By activating two incretin hormone receptors instead of one, tirzepatide may provide enhanced weight loss results compared to single-receptor medications.
Clinical trials have shown impressive results with tirzepatide, making it one of the most effective pharmaceutical options available for physician-supervised weight management.
How Tirzepatide Works
Tirzepatide activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. GLP-1 activation reduces appetite and slows gastric emptying, while GIP activation enhances insulin sensitivity and may provide additional metabolic benefits. The dual mechanism addresses multiple pathways involved in weight regulation and metabolic health.
Potential Benefits
- Dual receptor activation for enhanced results
- Clinically demonstrated significant weight loss
- Improved blood sugar and metabolic markers
- Reduced appetite and food cravings
- Once-weekly dosing for convenience
How It’s Administered
Tirzepatide is administered as a weekly subcutaneous injection. Dosing starts low and is titrated up gradually. Your Viking provider will monitor your progress and adjust your dose for optimal results with minimal side effects.
Is Tirzepatide Right for You?
Tirzepatide may be appropriate if you are looking for the most advanced pharmaceutical weight loss support available. Your Viking provider will evaluate your health profile and discuss whether tirzepatide or another GLP-1 based medication is the best fit. See also our page on GLP-1 Agonists for a broader overview.